Browse result page of AntiTbPdb
The total number entries retrieved from this search are 738
| ID | Name | Sequence | N-Terminal Modification | C-Terminal Modification | Chemical Modification | Linear/Cyclic | Length | Chirality | Nature | Source | Origin | Species | Strain | Inhibition Concentration | In vitro/ In vivo | Cell Line | Intracellular Inhibition | Cytotoxicity | Animal Model | Effective Dose in model organism | Immune Responce | Mechanism of Action | Target | Combination Therapy | Other Activities | Year of Publication | Pubmed ID/ Patent No. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| antitb_1421 | D-LAK120-H | KKLALHALKKWLHALKKLAHLALKK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis XDR strain | NA | in vitro | THP-1 cell line | EC50 = 32.2 ± 5.5 μM | Cytotoxic at12.5 μM | NA | NA | NA | NA | NA | NA | NA | 2014 | 25154927 |
| antitb_1422 | D-LAK120-HP13 | KKALAHALKKWLPALKKLAHALAKK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis XDR strain | NA | in vitro | THP-1 cell line | EC50 = 32.3 ± 4.7 μM | Cytotoxic above 3.13 μM | NA | NA | NA | NA | NA | NA | NA | 2014 | 25154927 |
| antitb_1423 | D-LAK120-H | KKLALHALKKWLHALKKLAHLALKK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis MDR strain GB2 | NA | Ex vivo | THP-1 cell line | NA | Cytotoxic at > 25 μM | NA | NA | NA | NA | NA | NA | NA | 2014 | 25154927 |
| antitb_1424 | D-LAK120-HP13 | KKALAHALKKWLPALKKLAHALAKK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis MDR strain GB2 | NA | Ex vivo | THP-1 cell line | NA | Cytotoxic at > 25 μM | NA | NA | NA | NA | NA | NA | NA | 2014 | 25154927 |
| antitb_1425 | D-LAK120-A | KKLALALAKKWLALAKKLALALAKK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis MDR strain GB2 | NA | Ex vivo | THP-1 cell line | NA | Cytotoxic at12.5 μM | NA | NA | NA | NA | NA | NA | NA | 2014 | 25154927 |
| antitb_1426 | D-LAk120-AP13 | KKLALALAKKWLPLAKKLALALAKK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis MDR strain GB2 | NA | Ex vivo | THP-1 cell line | NA | Cytotoxic above 3.13 μM | NA | NA | NA | NA | NA | NA | NA | 2014 | 25154927 |
| antitb_1427 | D-LAK120-H | KKLALHALKKWLHALKKLAHLALKK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis XDR strain WYC-11 | NA | Ex vivo | THP-1 cell line | NA | Cytotoxic at > 25 μM | NA | NA | NA | NA | NA | NA | NA | 2014 | 25154927 |
| antitb_1428 | D-LAK120-HP13 | KKALAHALKKWLPALKKLAHALAKK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis XDR strain WYC-11 | NA | Ex vivo | THP-1 cell line | NA | Cytotoxic at > 25 μM | NA | NA | NA | NA | NA | NA | NA | 2014 | 25154927 |
| antitb_1429 | D-LAK120-A | KKLALALAKKWLALAKKLALALAKK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis XDR strain WYC-11 | NA | Ex vivo | THP-1 cell line | NA | Cytotoxic at12.5 μM | NA | NA | NA | NA | NA | NA | NA | 2014 | 25154927 |
| antitb_1430 | D-LAk120-AP13 | KKLALALAKKWLPLAKKLALALAKK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis XDR strain WYC-11 | NA | Ex vivo | THP-1 cell line | NA | Cytotoxic above 3.13 μM | NA | NA | NA | NA | NA | NA | NA | 2014 | 25154927 |
| antitb_1431 | D-LAk120-AP13 | KKLALALAKKWLPLAKKLALALAKK | Free | Free | None | Linear | 25 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis XDR strain WYC-11 | MIC = 3.13 μM | In vitro | THP-1 cell line | NA | NA | NA | NA | NA | NA | NA | INH+D-LAK120-HP13 | NA | 2014 | 25154927 |
| antitb_1432 | Viomycin | H2N-CH-CH-CH-CH-R1-CH-NH2-Ch-CO-Nh-C-CO-NH-CH2OH-CO-NH-CH(CH2OH)-CO-NH-R2-CO-R3-HN-CH | Free | Free | R1=H, R2= >C=CHNHCONH2, R3=Tbd (Tuberactin) | NA | 38 | NA | NA | NA | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis 607 | MIC = 1.6 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial against Bacillus subtilis, Pseudomonas aeruginosa, proteus vulgaris, satphylococus aureous | 1977 | 197067 |
| antitb_1433 | Tuberactinomycin | H2N-CH-CH-CH-CH-R1-CH-NH2-Ch-CO-Nh-C-CO-NH-CH2OH-CO-NH-CH(CH2OH)-CO-NH-R2-CO-R3-HN-CH | Free | Free | R1 = OH, R2= >C=CHNHCONH2, R3 = Tbd (tuberactidine) | NA | 38 | NA | NA | NA | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis 607 | MIC = 3.1 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial against Bacillus subtilis, Pseudomonas aeruginosa, proteus vulgaris, satphylococus aureous | 1977 | 197067 |
| antitb_1434 | Tuberactinomycin O | H2N-CH-CH-CH-CH-R1-CH-NH2-Ch-CO-Nh-C-CO-NH-CH2OH-CO-NH-CH(CH2OH)-CO-NH-R2-CO-R3-HN-CH | Free | Free | R1 = H, R2 = >C=CHNHCONH2, R3 =Cpd (Capreomycidine) | NA | 38 | NA | NA | NA | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis 607 | MIC = 1.6 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial against Bacillus subtilis, Pseudomonas aeruginosa, proteus vulgaris, satphylococus aureous | 1977 | 197067 |
| antitb_1435 | Dihydroviomycin | H2N-CH-CH-CH-CH-R1-CH-NH2-Ch-CO-Nh-C-CO-NH-CH2OH-CO-NH-CH(CH2OH)-CO-NH-R2-CO-R3-HN-CH | Free | Free | None | NA | 38 | NA | NA | NA | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis 607 | MIC = 6.2 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial against Bacillus subtilis, Pseudomonas aeruginosa, proteus vulgaris, satphylococus aureous | 1977 | 197067 |
| antitb_1436 | Tetrahydroviomycin | H2N-CH-CH-CH-CH-R1-CH-NH2-Ch-CO-Nh-C-CO-NH-CH2OH-CO-NH-CH(CH2OH)-CO-NH-R2-CO-R3-HN-CH | Free | Free | R1 = H, r2 = >CH-OH, R3=Tbd(Tuberactidine) | NA | 38 | NA | NA | NA | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis 607 | MIC = 3.1 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial against Bacillus subtilis, Pseudomonas aeruginosa, proteus vulgaris, satphylococus aureous | 1977 | 197067 |
| antitb_1437 | Oxoviomycin | H2N-CH-CH-CH-CH-R1-CH-NH2-Ch-CO-Nh-C-CO-NH-CH2OH-CO-NH-CH(CH2OH)-CO-NH-R2-CO-R3-HN-CH | Free | Free | R1= H, R2 = > c=o, R3 = Tbd (Tuberactidine) | NA | 38 | NA | NA | NA | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis 607 | NA | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial against Bacillus subtilis, Pseudomonas aeruginosa, proteus vulgaris, satphylococus aureous | 1977 | 197067 |
| antitb_1438 | Broxoviomycin | H2N-CH-CH-CH-CH-R1-CH-NH2-Ch-CO-Nh-C-CO-NH-CH2OH-CO-NH-CH(CH2OH)-CO-NH-R2-CO-R3-HN-CH | Free | Free | R1 = H, r2 = >CH-OH, R3=Tbd(Tuberactidine) | NA | 38 | NA | NA | NA | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis 607 | MIC = 800 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial against Bacillus subtilis, Pseudomonas aeruginosa, proteus vulgaris, satphylococus aureous | 1977 | 197067 |
| antitb_1439 | A2-TB10.4 | IMYNYPAML | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1440 | A2-TB10.4 | AMLGHAGDM | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1441 | A2-TB10.4 | MLGHAGDMA | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1442 | A2-Ag85B | YLLDGLRAQ | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1443 | A2-Ag85B | KLVANNTRL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1444 | A2-Ag85B | FIYAGSLSA | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1445 | A2-ESAT6 | AMASTEGNV | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1446 | A2-ESAT | LLDEGKQSL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1447 | A2-Rv2958 | ALADLPVTV | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1448 | A2-Rv2957 | SIIIPTLNV | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1449 | A2-Rv0447 | VLAGSVDEL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv0447 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1450 | A24-TB10.4 | IMYNYPAML | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv0447 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1451 | A24-Ag85B | WYYQSGLSI | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1452 | A24-Ag85B | FLTSELPQW | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1453 | A24-Ag85B | IYAGSLSAL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1454 | A24-ESAT6 | AYQGVQQKW | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1455 | A24-ESAT6 | ELNNALQNL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1456 | A24-Rv2958 | KYIAADRKI | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1457 | A24-Rv2957 | PYNLRYRVL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1458 | A24-Rv0447 | KYIFPGGLL | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1459 | A3001-TB10.4 | QIMYNYPAM | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1460 | A3001-TB10.4 | LVRAYHAMS | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1461 | A3001-Rv2957 | IVLVRRWPK | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2957 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2957 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1462 | A3002-TB10.4 | QIMYNYPAM | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1463 | A3002-TB10.4 | IMYNYPAML | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1464 | A3002-TB10.4 | AMEDLVRAY | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1465 | A3002-ESAT6 | AMASTEGNV | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein ESAT6 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1466 | A3002-Rv2958 | SARLAGIPY | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv2958 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1467 | A3002-Rv0447 | RMWELYLAY | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv2958 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1468 | A68-TB10.4 | HAMSSTHEA | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Rv0447 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv0447 | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1469 | A68-TB10.4 | ANTMAMMAR | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein TB10.4 | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |
| antitb_1470 | A68-Ag85B | LPQWLSANR | Free | Free | None | Linear | 9 | L | NA | Protein derived | MTB derived protein Ag85B | Mycobacterium tuberculosis | Mycobacterium tuberculosis Rv | NA | NA | NA | NA | NA | NA | NA | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. | CD8+ T-cell | NA | NA | 2104 | 25809751 |